TABLE 2.

Change in anti‐acetylcholine receptor antibody concentration (multivariable logistic regression)

	Obs	Event, n (%)	n	OR	95% CI	p value
Model 1 a
Change in anti‐AChR‐ab concentration
Decrease ≥50%	53	46 (87)		4.39	1.79–10.74	0.001
Decrease 0%–50%	158	96 (61)		Reference	Reference	Reference
Increase	84	29 (35)		0.31	0.17–0.57	<0.001
Continuous (per 10% decrease)	295	171 (58)	90	1.21	1.12–1.31	<0.001
Model 2 b
Change in anti‐AChR‐ab concentration
Decrease ≥50%	53	46 (87)		4.11	1.67–10.15	0.002
Decrease 0%–50%	158	96 (61)		Reference	Reference	Reference
Increase	84	29 (35)		0.32	0.18–0.58	<0.001
Continuous (per 10% decrease)	295	171 (58)	90	1.21	1.12–1.30	<0.001
Model 3 c
Change in anti‐AChR‐ab concentration
Decrease ≥50%	47	41 (87)		3.65	1.40–9.54	0.008
Decrease 0%–50%	143	88 (62)		Reference	Reference	Reference
Increase	77	27 (35)		0.31	0.17–0.57	<0.001
Continuous (per 10% decrease)	267	156 (58)	82 d	1.19	1.10–1.29	<0.001

Event was defined as improvement in MGFA score.

Abbreviations: AChR‐ab, anti‐acetylcholine receptor; MGFA, Myasthenia Gravis Foundation of America; n, number of individuals; Obs, number of observations.

^a Additionally adjusted for time since baseline measurement (months; continuous).

^b Model 1 additionally adjusted for age (years), and sex (male/female).

^c Model 2 additionally adjusted for use of immunosuppressive medication (yes/no), thymectomy (yes/no), and time since thymectomy (days (centered), continuous).

^d Lower number of patients due to missing values for immunosuppressive medication use, and/or (time since) thymectomy.